TARGETING THE sarcomere TO IMPACT heart function

scientist testing potential medicines

Medicines & Research / Pipeline / Publications

Evaluation of Aficamten in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: REDWOOD HCM Cohort 4

Presentation, European Society of Cardiology Heart Failure 2023
Masri A, et al
Prague, Czech Republic
May 20, 2023

Long-Term Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Poster, ACC.23
Saberi S, et al
New Orleans, LA
March 4, 2023

Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)

Poster, ACC.23
Marsri A, et al
New Orleans, LA
March 4, 2023

Preclinical Characterization of CK-4021586, a New Class of Cardiac Myosin Inhibitors for the Treatment of Hypertrophic Cardiomyopathy

Poster, Biophysical Society Annual Meeting
Sarkar SS, et al
San Diego, CA
February 18, 2023

Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

Journal of the American College of Cardiology: Heart Failure
Lanfear DE, et al
February 1, 2023